Novo Nordisk A/S (NYSE:NVO) announced on Monday that Wegovy (semaglutide) injection 0.25 mg and 0.5 mg and Ozempic are now available at a limited-time price of $199 per month to new self-pay patients between now and March 31, 2026.

• NVO is gathering positive momentum. Check the fundamentals here.

The introductory offer is good for the first two months of therapy and applies to the two lowest doses (0.25 mg and 0.5 mg) of Wegovy or Ozempic.

After those two months, patients will move to the new standard monthly self-pay price, which Novo Nordisk is lowering from $499 to $349 per month, also beginning today.

These offers follow the recent agreement with the U.S. government to expand access to ...